샘플 요청 목록

 카트 문의
시장보고서
상품코드
1857394

세계의 아토피 피부염 치료제 시장

Atopic Dermatitis Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 179 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 아토피 피부염 치료제 시장은 2030년까지 384억 달러에 이를 전망

2024년에 122억 달러로 추정되는 아토피 피부염 치료제 세계 시장은 2024-2030년의 분석 기간에 CAGR 21.1%로 성장하여 2030년에는 384억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 생물제제는 CAGR 22.7%를 나타내고, 분석 기간 종료시에는 187억 달러에 이를 것으로 예측됩니다. 부신피질 스테로이드제 부문의 성장률은 분석 기간중 CAGR 21.2%로 추정됩니다.

미국 시장은 31억 달러로 추정, 중국은 CAGR 27.0%로 성장 예측

미국의 아토피 피부염 치료제 시장은 2024년에 31억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 105억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 27.0%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 15.5%와 18.6%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 17.4%를 보일 것으로 예측됩니다.

세계의 아토피 피부염 치료제 시장 - 주요 동향과 성장요인 정리

아토피피부염 치료제가 아토피피부염 관리에 필수적인 이유는 무엇인가?

아토피 피부염(일반적으로 습진으로 알려진)은 만성 염증성 피부질환으로 전 세계 수백만 명, 특히 어린이들이 앓고 있는 만성 염증성 피부질환입니다. 가려움증, 발적, 부종을 특징으로 하는 아토피 피부염은 환자의 삶의 질에 큰 영향을 미치고, 불편함, 수면장애, 심리적 스트레스까지 유발합니다. 아토피 피부염의 치료는 일반적으로 증상 완화, 재발 방지, 피부 장벽 기능 유지를 위한 외용제 치료, 전신 요법, 생활습관 개선이 병행됩니다. 코르티코스테로이드 외용제와 칼시뉴린 억제제는 염증을 억제하고 가려움증을 억제하여 증상을 완화하는 치료의 중심이 되어 왔습니다. 그러나 이 질환의 복잡한 면역학적 기전에 대한 이해가 높아짐에 따라 염증 과정에 관여하는 특정 경로를 표적으로 하는 새로운 약물이 등장하면서 치료 옵션도 확대되고 있습니다. 이러한 아토피피부염 치료제의 발전은 중등도에서 중증의 환자들에게 보다 효과적이고 타겟화된 치료 옵션을 제공하는 데 매우 중요합니다.

기술 혁신은 아토피 피부염 치료의 선택지를 어떻게 넓히고 있을까?

기술 혁신은 아토피 피부염 치료의 폭을 크게 넓히고, 새로운 약물 계열을 도입하여 보다 효과적인 치료법을 제공합니다. 가장 주목할 만한 진전 중 하나는 인터루킨-4(IL-4)와 인터루킨-13(IL-13)과 같은 염증 과정에 관여하는 특정 단백질을 표적으로 하는 생물학적 제제의 개발입니다. 듀피루맙과 같은 이러한 생물학적 제제는 기존 치료법으로 충분한 효과를 얻지 못하는 중등도에서 중증의 아토피피부염 환자에서 증상의 심각성을 완화시키는데 탁월한 효과를 보이고 있습니다. 또한, 야누스 키나아제(JAK) 억제제의 등장은 아토피 피부염에 관여하는 면역 신호 전달 경로를 조절할 수 있는 새로운 경구 치료 옵션을 제공하는 또 하나의 획기적인 발전입니다. 이 약제들은 기존 치료에 내성을 보이거나 견디지 못하는 환자들에게 대체 요법을 제공하는 약제입니다. 또한, 피부 침투력을 높이고 전신 흡수를 억제하는 국소 제제 등 약물 전달 시스템의 발전으로 아토피 피부염 치료의 안전성과 유효성이 향상되어 환자들에게 더욱 친숙하고 편리하게 다가갈 수 있게 되었습니다.

새로운 아토피 피부염 치료제의 채택을 촉진하는 시장 동향은?

보다 효과적이고 개인화된 치료 옵션에 대한 수요 증가를 반영하여, 몇 가지 주요 시장 동향이 새로운 아토피 피부염 치료제의 채택을 촉진하고 있습니다. 아토피 피부염의 유병률 증가, 특히 공해와 알레르겐 등 환경적 요인이 만연한 도시 지역에서는 고도의 치료에 대한 요구가 높아지고 있습니다. 또한, 아토피 피부염과 삶의 질에 미치는 영향에 대한 인식이 높아짐에 따라 더 많은 환자들이 치료를 받으려 하고, 효과적인 약품에 대한 수요가 증가하고 있습니다. 또한, 개인 맞춤형 의료 트렌드도 시장에 영향을 미치고 있으며, 의료진은 질병의 중증도, 동반 질환, 과거 치료 반응에 따라 환자 개개인에 맞는 치료 계획을 세우게 되었습니다. 또한, 원격의료와 디지털 헬스 플랫폼의 이용 확대로 피부과 의료에 대한 접근성이 향상되어 아토피피부염의 진단과 치료가 보다 적시에 이루어질 수 있게 되었습니다. 이러한 추세는 환자와 의료진이 최신의 가장 효과적인 치료 옵션을 찾는 가운데 아토피 피부염 치료제 시장의 급격한 성장에 기여하고 있습니다.

아토피 피부염 치료제 시장의 성장을 이끄는 요인은 무엇인가?

아토피 피부염 치료제 시장의 성장을 견인하는 것은 피부과 치료의 상황을 변화시키고 있는 몇 가지 요인들입니다. 첫 번째 요인은 전 세계적으로 아토피 피부염의 유병률이 증가함에 따라 효과적인 치료 옵션에 대한 수요가 증가하고 있다는 점입니다. 약물 개발의 기술적 진보, 특히 생물학적 제제 및 JAK 억제제의 도입은 중등도에서 중증의 환자에게 새롭고 효과적인 치료법을 제공함으로써 시장 성장을 가속하고 있습니다. 신흥 시장의 의료 인프라 확충과 피부과학 연구에 대한 투자 증가는 이러한 첨단 치료법의 이용 가능성과 채택을 더욱 촉진하고 있습니다. 또한, 환자 중심의 의료에 대한 관심 증가와 개인 맞춤형 의료의 추세는 환자 개개인의 특정 요구에 맞는 약물의 개발 및 사용을 촉진하고 있습니다. 이러한 요인들이 지속적으로 시장에 영향을 미치는 가운데, 아토피피부염 치료제 산업은 기술 혁신, 환자 인식 제고, 효과적인 치료법에 대한 수요 증가에 힘입어 지속적인 성장을 이룰 것으로 예측됩니다.

부문

약물 분류(생물학적 제제, 코르티코스테로이드, 피부 장벽 보습제, PDE4 억제제, 기타 약물 분류); 유통 채널(소매 약국, 병원 약국, 온라인 약국)

조사 대상 기업 예

  • Allergan Plc
  • Anacor Pharmaceutical Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Encore Dermatology
  • Leo Pharma
  • Meda Pharmaceuticals
  • Mylan
  • Novartis International AG
  • Pfizer
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Valent Pharmaceutical Inc.

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM를 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.11.10

Global Atopic Dermatitis Drugs Market to Reach US$38.4 Billion by 2030

The global market for Atopic Dermatitis Drugs estimated at US$12.2 Billion in the year 2024, is expected to reach US$38.4 Billion by 2030, growing at a CAGR of 21.1% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 22.7% CAGR and reach US$18.7 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 21.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 27.0% CAGR

The Atopic Dermatitis Drugs market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2030 trailing a CAGR of 27.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.5% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.4% CAGR.

Global Atopic Dermatitis Drugs Market - Key Trends and Drivers Summarized

Why Are Atopic Dermatitis Drugs Essential in Managing This Chronic Skin Condition?

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition that affects millions of individuals worldwide, particularly children. Characterized by itchy, red, and swollen skin, atopic dermatitis can significantly impact a patient's quality of life, leading to discomfort, sleep disturbances, and even psychological stress. The management of atopic dermatitis typically involves a combination of topical therapies, systemic treatments, and lifestyle modifications aimed at reducing symptoms, preventing flare-ups, and maintaining skin barrier function. Topical corticosteroids and calcineurin inhibitors have long been the cornerstone of treatment, providing relief by reducing inflammation and controlling itching. However, as our understanding of the disease's complex immunological mechanisms has evolved, so too have the therapeutic options available, with newer drugs targeting specific pathways involved in the inflammatory process. These advancements in atopic dermatitis drugs are crucial for providing more effective and targeted treatment options for patients suffering from moderate to severe forms of the disease.

How Are Technological Innovations Expanding Treatment Options for Atopic Dermatitis?

Technological innovations have significantly broadened the treatment landscape for atopic dermatitis, introducing new classes of drugs that offer more targeted and effective therapies. One of the most notable advancements has been the development of biologics, which are designed to target specific proteins involved in the inflammatory process, such as interleukin-4 (IL-4) and interleukin-13 (IL-13). These biologics, such as dupilumab, have shown remarkable efficacy in reducing the severity of symptoms in patients with moderate to severe atopic dermatitis who do not respond adequately to conventional therapies. Additionally, the emergence of Janus kinase (JAK) inhibitors represents another breakthrough, offering a new oral treatment option that can modulate immune signaling pathways implicated in atopic dermatitis. These drugs provide an alternative for patients who are either resistant to or cannot tolerate existing treatments. Furthermore, advancements in drug delivery systems, such as topical formulations that enhance skin penetration and reduce systemic absorption, are improving the safety and efficacy of atopic dermatitis therapies, making them more accessible and convenient for patients.

What Market Trends Are Driving the Adoption of New Atopic Dermatitis Drugs?

Several key market trends are driving the adoption of new atopic dermatitis drugs, reflecting the growing demand for more effective and personalized treatment options. The increasing prevalence of atopic dermatitis, particularly in urban areas where environmental factors such as pollution and allergens are more prevalent, has heightened the need for advanced therapies. Additionally, the rising awareness of atopic dermatitis and its impact on quality of life is prompting more patients to seek medical treatment, leading to higher demand for effective drugs. The trend towards personalized medicine is also influencing the market, with healthcare providers increasingly tailoring treatment plans to individual patients based on their disease severity, comorbidities, and response to prior therapies. Moreover, the expanding use of telemedicine and digital health platforms is improving access to dermatological care, enabling more timely diagnosis and treatment of atopic dermatitis. These trends are contributing to the rapid growth of the atopic dermatitis drug market, as patients and healthcare providers seek out the latest and most effective treatment options.

What Factors Are Driving the Growth of the Atopic Dermatitis Drug Market?

The growth in the atopic dermatitis drug market is driven by several factors that are reshaping the landscape of dermatological treatment. A primary driver is the increasing prevalence of atopic dermatitis globally, which is leading to greater demand for effective treatment options. Technological advancements in drug development, particularly the introduction of biologics and JAK inhibitors, are also fueling market growth by providing new and more effective therapies for patients with moderate to severe disease. The expansion of healthcare infrastructure in emerging markets, along with increasing investments in dermatological research, is further boosting the availability and adoption of these advanced therapies. Additionally, the growing focus on patient-centered care and the trend towards personalized medicine are driving the development and use of drugs that are tailored to the specific needs of individual patients. As these factors continue to influence the market, the atopic dermatitis drug industry is expected to experience sustained growth, driven by innovation, rising patient awareness, and the increasing demand for targeted and effective treatments.

SCOPE OF STUDY:

The report analyzes the Atopic Dermatitis Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors, Other Drug Classes); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 12 Featured) -

  • Allergan Plc
  • Anacor Pharmaceutical Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Encore Dermatology
  • Leo Pharma
  • Meda Pharmaceuticals
  • Mylan
  • Novartis International AG
  • Pfizer
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Valent Pharmaceutical Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Atopic Dermatitis Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Atopic Dermatitis Propels Growth in Therapeutics Market
    • Increasing Demand for Personalized Medicine Expands Addressable Market Opportunity
    • Innovation in Drug Delivery Systems Drives Adoption of Topical and Oral Therapies
    • Growing Awareness of Atopic Dermatitis Among Patients Spurs Market Growth
    • Impact of Environmental Factors on Atopic Dermatitis Incidence Accelerates Demand for Advanced Treatments
    • Emergence of Personalized Treatment Plans Expands Opportunities for Tailored Therapies
    • Increasing Use of Biologics in Pediatric Patients Drives Adoption of New Therapies
    • Shift Towards Non-Steroidal Treatments Generates New Market Opportunities
    • Innovations in Immunomodulatory Drugs Strengthen Case for Targeted Atopic Dermatitis Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Atopic Dermatitis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Atopic Dermatitis Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Skin Barrier Emollients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Skin Barrier Emollients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Skin Barrier Emollients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for PDE4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for PDE4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for PDE4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Atopic Dermatitis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Atopic Dermatitis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Atopic Dermatitis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Atopic Dermatitis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Atopic Dermatitis Drugs by Drug Class - Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Atopic Dermatitis Drugs by Drug Class - Percentage Breakdown of Value Sales for Biologics, Corticosteroids, Skin Barrier Emollients, PDE4 Inhibitors and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Atopic Dermatitis Drugs by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Atopic Dermatitis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제